Status:
COMPLETED
Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee
Lead Sponsor:
Pfizer
Conditions:
Osteoarthritis,Knee
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in ...
Eligibility Criteria
Inclusion
- diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
- patients in flare
Exclusion
- any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
- clinical or radiological evidence of chondrocalcinosis
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00137410
Start Date
November 1 2002
End Date
March 1 2006
Last Update
June 10 2008
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Rutigliano, BA, Italy, 70018
2
Pfizer Investigational Site
Arenzano (GE), Italy, 16011
3
Pfizer Investigational Site
Cagliari - Monserrato, Italy
4
Pfizer Investigational Site
Foggia, Italy, 71100